BR112012011457A2 - uso antitumoral de cabazitaxel. - Google Patents
uso antitumoral de cabazitaxel.Info
- Publication number
- BR112012011457A2 BR112012011457A2 BR112012011457A BR112012011457A BR112012011457A2 BR 112012011457 A2 BR112012011457 A2 BR 112012011457A2 BR 112012011457 A BR112012011457 A BR 112012011457A BR 112012011457 A BR112012011457 A BR 112012011457A BR 112012011457 A2 BR112012011457 A2 BR 112012011457A2
- Authority
- BR
- Brazil
- Prior art keywords
- cabazitaxel
- antitumor
- prostate cancer
- antitumor use
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Abstract
patente de invenção: uso antitumoral de cabazitaxel. a presente invenção refere-se a um composto de fórmula (i): que pode estar na forma de base ou na forma de um hidrato ou de um solvato, em combinação com prednisona ou prednisolona, para uso como medicamento no tratamento de câncer de próstata, particularmente câncer de próstata metastático, especialmente para pacientes que não recebem qualquer tratamento à base de taxano.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25616009P | 2009-10-29 | 2009-10-29 | |
US29390310P | 2010-01-11 | 2010-01-11 | |
US35588810P | 2010-06-17 | 2010-06-17 | |
US35583410P | 2010-06-17 | 2010-06-17 | |
US36992910P | 2010-08-02 | 2010-08-02 | |
US38393310P | 2010-09-17 | 2010-09-17 | |
US38996910P | 2010-10-05 | 2010-10-05 | |
PCT/IB2010/054866 WO2011051894A1 (en) | 2009-10-29 | 2010-10-27 | Novel antitumoral use of cabazitaxel |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012011457A2 true BR112012011457A2 (pt) | 2016-05-03 |
Family
ID=43567614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012011457A BR112012011457A2 (pt) | 2009-10-29 | 2010-10-27 | uso antitumoral de cabazitaxel. |
Country Status (30)
Country | Link |
---|---|
US (8) | US8927592B2 (pt) |
EP (1) | EP2493466B1 (pt) |
JP (2) | JP5566466B2 (pt) |
KR (1) | KR101712231B1 (pt) |
CN (1) | CN102770131A (pt) |
AR (1) | AR078824A1 (pt) |
AU (4) | AU2010310986A1 (pt) |
BR (1) | BR112012011457A2 (pt) |
CA (1) | CA2779009A1 (pt) |
CR (1) | CR20120204A (pt) |
DK (1) | DK2493466T3 (pt) |
EA (1) | EA024186B1 (pt) |
EC (1) | ECSP12011836A (pt) |
ES (1) | ES2862340T3 (pt) |
GT (1) | GT201200123A (pt) |
IL (3) | IL219443A0 (pt) |
MA (1) | MA33767B1 (pt) |
MX (1) | MX336339B (pt) |
MY (1) | MY164086A (pt) |
NI (1) | NI201200071A (pt) |
PE (1) | PE20121429A1 (pt) |
PL (1) | PL2493466T3 (pt) |
PT (1) | PT2493466T (pt) |
SG (1) | SG10201810928SA (pt) |
SV (1) | SV2012004192A (pt) |
TN (1) | TN2012000188A1 (pt) |
TW (2) | TWI654975B (pt) |
UY (1) | UY32987A (pt) |
WO (1) | WO2011051894A1 (pt) |
ZA (1) | ZA201203123B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
US20120065255A1 (en) * | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
PE20121429A1 (es) * | 2009-10-29 | 2012-11-06 | Aventis Pharma Sa | Nuevo uso antitumoral de cabazitaxel |
EA023950B1 (ru) * | 2011-04-12 | 2016-07-29 | Тева Фармасьютикалз Интернэшнл Гмбх | Твердофазные формы кабазитаксела и способы их получения |
CN102503913B (zh) * | 2011-10-20 | 2014-03-26 | 江苏红豆杉生物科技股份有限公司 | 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法 |
JP6025861B2 (ja) * | 2011-12-13 | 2016-11-16 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの結晶形およびこれを調製するための方法 |
US9403785B2 (en) * | 2012-01-03 | 2016-08-02 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
CN104583189A (zh) | 2012-07-31 | 2015-04-29 | 永信药品工业股份有限公司 | 非晶型的卡巴利他索 |
TW201827417A (zh) * | 2013-03-04 | 2018-08-01 | 法商安萬特醫藥公司 | 卡巴他賽(cabazitaxel)及其治療轉移性前列腺癌之用途 |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
US10555926B2 (en) * | 2015-02-17 | 2020-02-11 | Erasmus University Medical Center Rotterdam | Use of cabazitaxel in the treatment of prostate cancer |
EP3093014A1 (en) * | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
WO2018047074A1 (en) | 2016-09-07 | 2018-03-15 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
US20170281651A1 (en) | 2017-03-01 | 2017-10-05 | Corcept Therapeutics, Inc. | Concomitant administration of glucocorticoid receptor modulators and cyp3a or steroidogenesis inhibitors |
US20210088505A1 (en) * | 2017-04-07 | 2021-03-25 | La Jolla Institute For Allergy And Immunology | Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5005588A (en) | 1989-10-13 | 1991-04-09 | David Rubin | Method for increasing tumor sensitivity to chemotherapy |
US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
FR2732340B1 (fr) | 1995-03-27 | 1997-04-30 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
ZA94128B (en) | 1993-02-01 | 1994-08-19 | Univ New York State Res Found | Process for the preparation of taxane derivatives and betalactam intermediates therefor |
MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
US6372780B2 (en) | 1995-03-27 | 2002-04-16 | Aventis Pharma S.A. | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
US5847170A (en) | 1995-03-27 | 1998-12-08 | Rhone-Poulenc Rorer, S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
FR2745814B1 (fr) | 1996-03-06 | 1998-04-03 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2771092B1 (fr) | 1997-11-18 | 1999-12-17 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la classe des taxoides |
US6346543B1 (en) | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
EP1105119A2 (en) | 1998-08-20 | 2001-06-13 | Aventis Pharma S.A. | New use of taxoid derivatives |
US6403634B1 (en) | 1999-01-13 | 2002-06-11 | Aventis Pharma S.A. | Use of taxoid derivatives |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
ATE302685T1 (de) | 2003-07-02 | 2005-09-15 | Scheuten Glasgroep Bv | Verfahren zur herstellung einer brandschutzverglasung |
EP1498120A1 (en) | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
FR2859996B1 (fr) * | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
GB0425854D0 (en) | 2004-11-25 | 2004-12-29 | Astrazeneca Ab | Therapeutic treatment |
KR101357040B1 (ko) | 2004-12-08 | 2014-02-03 | 아벤티스 파마슈티칼스 인크. | 도세탁셀에 대한 내성 또는 감수성을 측정하는 방법 |
EP1700596A1 (en) | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
FR2922107B1 (fr) | 2007-10-10 | 2010-02-26 | Aventis Pharma Sa | Nouvelles compositions a base de taxoides |
FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
EP2177630A1 (en) | 2008-10-02 | 2010-04-21 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
CA2756072A1 (en) | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
FR2945211A1 (fr) | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
EA201200486A1 (ru) | 2009-09-15 | 2012-08-30 | Серулин Фарма Инк. | Лечение онкологических заболеваний |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
PE20121429A1 (es) | 2009-10-29 | 2012-11-06 | Aventis Pharma Sa | Nuevo uso antitumoral de cabazitaxel |
EP2330100B1 (en) | 2009-11-04 | 2017-01-11 | Emcure Pharmaceuticals Limited | An improved process for preparation of taxane derivatives |
CN102781237A (zh) | 2009-11-23 | 2012-11-14 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
US20130130928A1 (en) | 2010-04-08 | 2013-05-23 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
WO2011130317A2 (en) | 2010-04-13 | 2011-10-20 | Amplyx Pharmaceuticals Inc. | Therapeutic agents having reduced toxicity |
WO2011130566A2 (en) | 2010-04-16 | 2011-10-20 | Bellicum Pharmaceuticals, Inc. | Method for treating solid tumors |
-
2010
- 2010-10-27 PE PE2012000581A patent/PE20121429A1/es not_active Application Discontinuation
- 2010-10-27 CN CN2010800600528A patent/CN102770131A/zh active Pending
- 2010-10-27 MY MYPI2012001871A patent/MY164086A/en unknown
- 2010-10-27 SG SG10201810928SA patent/SG10201810928SA/en unknown
- 2010-10-27 BR BR112012011457A patent/BR112012011457A2/pt not_active Application Discontinuation
- 2010-10-27 ES ES10782039T patent/ES2862340T3/es active Active
- 2010-10-27 DK DK10782039.1T patent/DK2493466T3/da active
- 2010-10-27 EA EA201270606A patent/EA024186B1/ru not_active IP Right Cessation
- 2010-10-27 JP JP2012535996A patent/JP5566466B2/ja active Active
- 2010-10-27 PL PL10782039T patent/PL2493466T3/pl unknown
- 2010-10-27 CA CA2779009A patent/CA2779009A1/en not_active Abandoned
- 2010-10-27 MX MX2012005030A patent/MX336339B/es unknown
- 2010-10-27 KR KR1020127013564A patent/KR101712231B1/ko active IP Right Grant
- 2010-10-27 PT PT107820391T patent/PT2493466T/pt unknown
- 2010-10-27 EP EP10782039.1A patent/EP2493466B1/en active Active
- 2010-10-27 WO PCT/IB2010/054866 patent/WO2011051894A1/en active Application Filing
- 2010-10-27 AU AU2010310986A patent/AU2010310986A1/en not_active Abandoned
- 2010-10-29 TW TW104143630A patent/TWI654975B/zh active
- 2010-10-29 TW TW099137327A patent/TWI533866B/zh active
- 2010-10-29 AR ARP100103990 patent/AR078824A1/es unknown
- 2010-10-29 UY UY32987A patent/UY32987A/es unknown
-
2012
- 2012-04-25 TN TNP2012000188A patent/TN2012000188A1/en unknown
- 2012-04-25 CR CR20120204A patent/CR20120204A/es unknown
- 2012-04-25 IL IL219443A patent/IL219443A0/en unknown
- 2012-04-26 US US13/456,720 patent/US8927592B2/en active Active
- 2012-04-26 GT GT201200123A patent/GT201200123A/es unknown
- 2012-04-27 SV SV2012004192A patent/SV2012004192A/es unknown
- 2012-04-27 EC ECSP12011836 patent/ECSP12011836A/es unknown
- 2012-04-27 NI NI201200071A patent/NI201200071A/es unknown
- 2012-04-30 ZA ZA2012/03123A patent/ZA201203123B/en unknown
- 2012-05-25 MA MA34898A patent/MA33767B1/fr unknown
-
2014
- 2014-06-16 JP JP2014123108A patent/JP6182510B2/ja active Active
- 2014-12-18 US US14/575,578 patent/US20150118182A1/en not_active Abandoned
- 2014-12-18 US US14/575,566 patent/US20150104411A1/en not_active Abandoned
-
2016
- 2016-02-01 AU AU2016200598A patent/AU2016200598A1/en not_active Abandoned
-
2017
- 2017-01-24 IL IL250254A patent/IL250254A0/en unknown
- 2017-06-20 US US15/627,962 patent/US10583110B2/en active Active
- 2017-09-25 AU AU2017232227A patent/AU2017232227B2/en not_active Ceased
-
2019
- 2019-01-18 US US16/251,143 patent/US20190151278A1/en not_active Abandoned
- 2019-05-20 AU AU2019203514A patent/AU2019203514A1/en not_active Abandoned
- 2019-06-23 IL IL267583A patent/IL267583A/en unknown
-
2020
- 2020-01-15 US US16/743,411 patent/US10716777B2/en active Active
- 2020-07-17 US US16/931,802 patent/US20210169843A1/en not_active Abandoned
-
2023
- 2023-07-20 US US18/224,122 patent/US20240139146A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012011457A2 (pt) | uso antitumoral de cabazitaxel. | |
BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
PA8740901A1 (es) | Compuestos organicos | |
CR20120213A (es) | Métodos para el tratamiento del cáncer usando antagonistas de notch | |
BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
CL2008001047A1 (es) | Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata. | |
CL2007002994A1 (es) | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
CU20120042A7 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
BR112015006705A2 (pt) | antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático | |
CO7071139A2 (es) | Tratamiento contra el cáncer cerebral | |
CL2013003324A1 (es) | Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón. | |
BR112015026292A8 (pt) | composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da dna-pk, bem como kit | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
CR20150442A (es) | Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos | |
UY32555A (es) | Nuevos derivados de quinazolinadiona | |
MX2011006532A (es) | Compuestos anticancerigenos. | |
CO6531492A2 (es) | Nuevo uso antitumoral de cabazitaxel | |
DOP2012000118A (es) | Nuevo uso antitumoral de cabazitaxel | |
BR112014021809A2 (pt) | aminometileno pirazolonas com atividade terapêutica | |
PH12014501794A1 (en) | New pediatric uses of cabazitaxel | |
TN2014000342A1 (en) | New pediatric uses of cabazitaxel | |
BR112015001515A2 (pt) | compostos terapêuticos | |
TH135898A (th) | การใช้สารต้านเนื้องอกชนิดใหม่ของคาบาซิทาเซล |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |